Conference Correspondent

Conference Correspondent

In this long-term efficacy and safety analysis of the global phase 3 SIRROUND-D trial, improvements in signs and symptoms of rheumatoid arthritis (RA) and health-related physical and emotional well-being were maintained with sirukumab treatment in patients with active RA despite disease-modifying antirheumatic drugs (DMARDs).
Results of the randomized, placebo-controlled, phase 3 SELECT-NEXT study showed that upadacitinib, a selective JAK-1 inhibitor, at 15 mg and 30 mg once daily, was efficacious in patients with rheumatoid arthritis (RA) who had inadequate response to conventional synthetic disease-modifying antirheumatic drugs (DMARDs), with a safety and tolerability profile that was consistent with that previously reported.

This cost-per-responder analysis of patients treated on the MONARCH trial showed that sarilumab was more economically dominant compared with adalimumab with respect to incremental costs per response for patients with active, moderate-to-severe rheumatoid arthritis (RA).

This post-hoc analysis showed that the efficacy of sarilumab was maintained or improved in patients with rheumatoid arthritis (RA) who switched or continued into the open-label EXTEND trial to receive sarilumab 200 mg every 2 weeks (q2w) after completion of the ASCERTAIN trial, with particularly increased efficacy occurring in those who initially received tocilizumab or sarilumab 150 mg q2w

Results of this post-hoc analysis of the TARGET study demonstrated that patients with active, moderate-to-severe rheumatoid arthritis (RA) and inadequate response to tumor necrosis factor (TNF) inhibitors treated with sarilumab 150 mg or 200 mg every 2 weeks on a conventional synthetic disease-modifying antirheumatic drug (csDMARD) background achieved greater clinical responses compared with those treated with placebo, regardless of baseline disease activity. However, a greater sarilumab treatment effect was achieved by patients with higher baseline disease activity.

In this analysis of the TARGET study, a sustained clinically significant response was achieved by more patients with active, moderate-to-severe rheumatoid arthritis (RA) and inadequate response to, or intolerance of, tumor necrosis factor (TNF) inhibitors treated with sarilumab plus conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) versus those treated with placebo plus csDMARDs.

This study conducted using the Corrona Rheumatoid Arthritis (RA) registry dataset demonstrated that tocilizumab monotherapy improved disease activity as effectively as tumor necrosis factor inhibitors (TNFis) plus any dose of methotrexate (MTX) in patients with prior TNFi exposure in routine clinical practice, suggesting that it is an effective alternate treatment option for patients who cannot tolerate or prefer not to use MTX.

An updated integrated analysis of patients (n = 3492) with moderately to severely active rheumatoid arthritis (RA), including patients exposed to any dose of baricitinib for up to 5.5 years, showed that the safety profile of baricitinib was maintained as similar to that previously reported.
A cardiac MRI follow-up study showed that patients with active rheumatoid arthritis (RA) show myocardial abnormalities at baseline, which significantly improved in patients with early RA following active treatment for 1 year.
A real-world analysis of electronic health record (EHR) databases across Integrated Delivery Networks showed lower EHR reporting rates of clinical and disease severity measures, thus compromising the ability of rheumatologists to adopt a guideline-recommended treat-to-target approach in clinical practice.
Page 8 of 19
Results 71 - 80 of 190
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME